Hebei Senlang Biotechnology Inc., Ltd.
Clinical trials sponsored by Hebei Senlang Biotechnology Inc., Ltd., explained in plain language.
-
New CAR t therapy aims to tackle tough multiple myeloma
Disease control Not yet recruitingThis early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingThis study tests a new treatment called S101 CAR-T cells for people with a type of T-cell cancer (T-LBL/ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. Th…
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC